July 11, 2013 | Several of the recent and upcoming biotech IPOs have one thing in common: a partnership with Celgene. In their work with start ups a few Celgene habits stand out: a hands off approach, high-risk/high-reward picks, and flexibility in the deal. Senior VP of Business Development talks with Xconomy about how it works. Xconomy